Glaucoma surgeons need a predictable surgical option to deliver intraocular pressures (IOPs) of 11-15 mmHg, with predictable and manageable post-op follow-up and safety outcomes (1, 2). And that is exactly what the PRESERFLO™ MicroShunt glaucoma drainage system offers. Not only are results consistent, but the device is safe and effective for those patients with primary open-angle glaucoma (POAG) who require IOP lowered to below 15 mmHg (1, 2).
The device answers this specific market need with its innovative design, featuring SIBS material, which ensures a reduction of IOP while significantly reducing the risk of hypotony compared with trabeculectomy (2). Importantly, the device enables an ab externo approach that provides surgeons with more control (compared with ab interno) during a sub conjunctival procedure.
The PRESERFLO MicroShunt’s ability to consistently deliver sustained IOP of 11-15 mmHg with predictable safety outcomes in glaucoma procedures boil down to one important word for surgeons: confidence (1, 2). In particular, the reduced post-op management is a major advantage – and even more important during the COVID-19 period. Moreover, the straightforward procedure allows surgeons to perform more PRESERFLO™ MicroShunt surgeries in the same time it would take them to do a single trabeculectomy.
But the benefits don’t end with the surgeon; a primary European study for PRESERFLO™ MicroShunt published in late 2021 shows that the device reduces the need for topical antiglaucoma medications; after two years, 73.8 percent of patients were medication free, and 80 percent of patients were classified as having complete success – with at least a 20 percent IOP reduction from baseline, and medication free. Other key results included a significant IOP reduction from the baseline – average IOP being at 14.1 mmHg by year two, with a 34.1 percent reduction, and a needling rate of 6.2 percent (3).
The PRESERFLO™ MicroShunt is an ideal solution for POAG patients who have uncontrolled IOP and are on the maximum tolerated medical therapy, where glaucoma progression warrants surgical intervention or where combined surgery is advised.
The success of the PRESERFLO™ MicroShunt feeds into Santen’s overall strategy; the company’s goal towards 2030 and beyond is to become a social innovator – orchestrating and mobilizing key technologies and players around the world to deliver happiness through vision.
Job code: PP-PMS-EMEA-0278
Date of preparation: November 2021
References
- JF Battle et al., “Long-term results of the PRESERFLO MicroShunt in patients with primary open-angle glaucoma from a single-center nonrandomized study,” J Glaucoma, 30, 281 (2021). PMID: 33137019.
- ND Baker et al., “Ab-externo MicroShunt versus trabeculectomy in primary open-angle glaucoma: one-year results from a 2-year randomized, multicenter study,” Ophthalmology, 128, 1710 (2021). PMID: 34051211.
- HJM Beckers et al., “Safety and effectiveness of the PRESERFLO® MicroShunt in primary open-angle glaucoma: results from a 2-year multicenter study,” Ophthalmol Glaucoma, [Online ahead of print] (2021). PMID: 34329772.
